Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”